Healthy, no Evidence of Disease Clinical Trial
Official title:
Phase I Dose-Finding Trial of Letrozole in Postmenopausal Women at High Risk for Breast Cancer
This randomized phase I trial studies the side effects and the best dose of letrozole in preventing breast cancer in healthy postmenopausal women at high risk for breast cancer. Chemoprevention is the use of drugs to keep breast cancer from forming or coming back. The use of letrozole may keep cancer from forming in healthy postmenopausal women at high risk for breast cancer.
Status | Completed |
Enrollment | 112 |
Est. completion date | |
Est. primary completion date | June 2014 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 35 Years and older |
Eligibility |
Inclusion Criteria: - Healthy postmenopausal women at "high risk" for breast cancer will be eligible for the study; definition of menopause will be: - Amenorrhea for at least 12 months, or - History of hysterectomy and bilateral salpingo-oophorectomy, or - At least 55 years of age with prior hysterectomy with or without oophorectomy, or - Age 35 to 54 with a prior hysterectomy without oophorectomy OR with a status of ovaries unknown with documented follicle-stimulating hormone level demonstrating elevation in postmenopausal range - "High risk" for breast cancer will be defined as: - Prior histologically confirmed lobular carcinoma in situ (LCIS) treated by local excision only, or - At least 1.66% probability of invasive breast cancer within 5 years using the Breast Cancer Risk Assessment Tool - Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1; Karnofsky 80% or above - Leukocytes >= 3,000/uL - Absolute neutrophil count >= 1,500/uL - Platelets >= 100,000/uL - Total bilirubin =< 2.0 mg/dL - Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.0 X institutional ULN - Creatinine =< 1 X institutional ULN - Recent mammogram negative for breast cancer, Breast Imaging-Reporting and Data System (BIRADS) score < 3 (within the last 12 months) - Ability to understand and the willingness to sign a written informed consent document; only potential participants with the ability to understand and the willingness to sign a written document will be presented with an informed consenting document Exclusion Criteria: - Women diagnosed with osteoporosis (previously or on screening dual-energy X-ray absorptiometry [DEXA] for this study) and not on a stable dose of long or short-acting bisphosphonates therapy for at least 3 months will be excluded from the study; women diagnosed with osteoporosis and on raloxifene (Evista) therapy will be excluded from the study; use of calcium and/or vitamin D for osteoporosis prevention or treatment is allowed; women with osteopenia will be allowed to participate in this study - Have had invasive cancer within the past five years except non-melanoma skin cancer - Evidence of suspicious of malignant disease on bilateral mammogram within the past year unless ruled out by further evaluation - History of prior invasive breast cancer or intraductal carcinoma in situ, or history of prior radiation therapy to the chest or breast - Participants may not be receiving any other investigational agents; participants may not be concurrently enrolled in another breast cancer prevention intervention trial - History of allergic reactions attributed to compounds of similar chemical or biologic composition to letrozole - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements - Within 3 months since prior estrogen or progesterone replacement therapy, oral contraceptives, androgens, luteinizing hormone-releasing hormone analogs, prolactin inhibitors, or antiandrogens - Within 3 months since prior tamoxifen, raloxifene, or other selective estrogen-receptor modulators - Within 3 months since regular use (more than 2 times a week) of prior estrogenic supplements or herbal remedies - History of bleeding or clotting disorder; current or recent (within 3 months) use of Coumadin, Plavix or other systemic anticoagulant other than aspirin is not permitted if subject chooses to participate in the optional RPFNA procedure; if a subject chooses not to participate in the RPFNA procedure, prior or current treatment with systemic anticoagulants is permitted |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
United States | Mayo Clinic | Rochester | Minnesota |
United States | Arizona Cancer Center - Tucson | Tucson | Arizona |
United States | University of Arizona Health Sciences Center | Tucson | Arizona |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Prevalence of breast cancer stem cells by the proportion of aldehyde dehydrogenase positive cells, assessed by the Aldeflour assay | Up to week 30 | No | |
Other | Relative expression of stem cell markers to housekeeping genes, assessed by quantitative real time polymerase chain reaction | Up to week 30 | No | |
Primary | Percentage of serum estradiol suppression in postmenopausal women at high risk for breast cancer | Three one-sided two-sample t-tests will be conducted on the ratios of the mean percentage of suppression simultaneously to test for non-inferiority. A multivariate t-distribution is used to derive the critical value and the power. | Baseline to week 30 | No |
Secondary | Change in serum estrone levels | Three one-sided two-sample t-tests will be performed to evaluate the ratio of the mean changes (or percentage of changes) of each of the three intermittent dosing groups to that of the standard therapy control group simultaneously for each of the endpoints at an overall significance level of 5%. | Baseline to week 30 | No |
Secondary | Change in serum testosterone levels | Three one-sided two-sample t-tests will be performed to evaluate the ratio of the mean changes (or percentage of changes) of each of the three intermittent dosing groups to that of the standard therapy control group simultaneously for each of the endpoints at an overall significance level of 5%. | Baseline to week 30 | No |
Secondary | Menopausal symptoms as assessed by quality of life measures, as assessed by Medical Outcomes Study 36-item Short Form Health Survey (SF-36) and Menopause Specific Quality of Life Questionnaire (MENQOL) | Up to week 30 | No | |
Secondary | Nuclear chromatin abnormality as assessed by karyometry | Up to week 30 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01950403 -
Linaclotide Acetate in Preventing Colorectal Cancer in Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT01336387 -
Dose-Finding of Retinoid 9cUAB30 in Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT01561989 -
Cholecalciferol and Flu Vaccine in Treating Healthy Participants
|
N/A | |
Completed |
NCT01140646 -
Evaluation of SAMe for Hot Flashes
|
Phase 2 | |
Completed |
NCT00892515 -
Exercise Programs in Healthy Young Women at Increased Risk of Developing Breast Cancer
|
N/A | |
Completed |
NCT00365209 -
Phase II A Trial of Curcumin Among Patients With Prevalent Subclinical Neoplastic Lesions (Aberrant Crypt Foci)
|
Phase 2 | |
Completed |
NCT00450957 -
Lycopene in Healthy Male Participants
|
Phase 1 | |
Recruiting |
NCT04445532 -
Hepatobiliary Tumors Tissue Samples Acquisition
|
||
Completed |
NCT02100254 -
Narrative or Fact-Based Videos in Increasing Colorectal Cancer Screenings in African American Communities
|
N/A | |
Completed |
NCT02129517 -
Web-Based Tailored Educational Program in Improving Nurse Communication With Patients About Clinical Trials
|
N/A | |
Terminated |
NCT01755208 -
Light-Scattering Spectroscopy for Detection of Breast Cancer
|
N/A | |
Completed |
NCT00392652 -
Diindolylmethane in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00499460 -
Effects of Garlic Supplements on Opioids in Healthy Volunteers
|
Phase 4 | |
Completed |
NCT00478309 -
Genetic Epidemiology Risk Assessment Program or Usual Care in Colorectal Cancer Screening for Healthy Participants
|
N/A | |
Completed |
NCT01370889 -
Resveratrol in Postmenopausal Women With High Body Mass Index
|
Phase 1 | |
Completed |
NCT00896207 -
Studying Different Formulations of SR13668 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00679094 -
Bowman-Birk Inhibitor Concentrate in Healthy Men
|
Phase 1 | |
Terminated |
NCT02154984 -
Time Restricted Diet in Obese or Overweight Pre or Postmenopausal Participants
|
N/A | |
Completed |
NCT00489372 -
Se-Methyl-Seleno-L- Cysteine (MSC) in Treating Healthy Patients
|
Phase 1 | |
Completed |
NCT00513916 -
Effect of Dietary Soy on Estrogens in Breast Fluid, Blood, and Urine Samples From Healthy Women
|
Phase 3 |